Renalytix PLC has announced a collaboration with Tempus AI to expand access to its FDA-approved kidneyintelX.dkd prognostic blood test for patients with type 2 diabetes and chronic kidney disease in the US.

This partnership emphasizes AI-enabled diagnostics to improve kidney disease management, with the test already FDA-approved and reimbursed by Medicare, aiming to support earlier intervention and better clinical outcomes.

The collaboration seeks to enhance clinical outcomes and quality metrics by integrating the test into clinical workflows through electronic reporting and seamless data sharing with clinicians and patient portals.

Leveraging Tempus's extensive clinical network and AI platform, the partnership will facilitate the integration of the test into existing healthcare workflows, promoting wider adoption.

This marks Tempus's entry into the chronic kidney disease diagnostic space, with the goal of accelerating adoption by embedding the test into healthcare providers' routines.

Renalytix's CEO, James McCullough, highlighted that the partnership will significantly expand patient and clinician access, fostering innovation in cardiovascular-renal-metabolic diagnostics and therapeutics.

Chronic Kidney Disease affects over 850 million people worldwide, including more than 35 million adults in the US, many of whom are unaware of their condition, leading to over $130 billion in Medicare costs annually.

The collaboration involves working with US health systems to incorporate the kidneyintelX.dkd test into existing clinical workflows, improving early detection and management of kidney disease.

By making testing more accessible, the partnership aims to address a major global health issue and improve outcomes for millions affected by CKD.

The kidneyintelX.dkd test will be processed in Renalytix's laboratories, with results electronically reported to clinicians and patients to enable timely interventions and slow disease progression.

This partnership aims to leverage Tempus's broad US healthcare network and clinical platform to make the test more widely available, supporting personalized medicine and better clinical outcomes.

Tempus, a leader in AI-driven precision medicine, brings its extensive data library and technology to facilitate the discovery and development of therapeutics, marking a significant step into the CKD diagnostic space.